IL17RA

Green IL17RA in COVID-19 research

Level 2: Viral research
Version 1.142

Sources

• IUIS Classification February 2018
• London North GLH
• NHS GMS
• GRID V2.0
• Victorian Clinical Genetics Services
• North West GLH
• ESID Registry 20171117
• Expert Review Green
• NHS GMS
• North West GLH
• London North GLH
• Expert Review Green
• IUIS Classification February 2018
• Victorian Clinical Genetics Services
• ESID Registry 20171117
• GRID V2.0

Phenotypes

• Candidiasis, familial, 5
• Chronic mucocutaneous candidiasis (CMC)
• Immunodeficiency 51, 613953
• CMC, folliculitis
• Defects in Intrinsic and Innate Immunity

Green IL17RA in Primary immunodeficiency or monogenic inflammatory bowel disease

Version 5.1
Latest signed off version: v5.0 (1 May 2024)

Sources

• NHS GMS
• North West GLH
• London North GLH
• Expert Review Green
• IUIS Classification February 2018
• Victorian Clinical Genetics Services
• ESID Registry 20171117
• GRID V2.0

Phenotypes

• Immunodeficiency 51, OMIM:613953

Green IL17RA in Severe Paediatric Disorders

Version 1.184

Sources

• Next Generation Children Project
• Expert Review Green
• Expert list

Phenotypes

• Immunodeficiency 51, 613953

Amber IL17RA in Autoinflammatory disorders

Level 3: Primary immunodeficiency disorders
Level 2: Haematological disorders
Version 2.1
Latest signed off version: v2.0 (1 May 2024)

Sources

• Expert Review Amber
• Literature

Phenotypes

• Immunodeficiency 51, OMIM:613953

Tags

• watchlist